US Cell and Gene Therapy Multiple Myeloma Market Size, Share, Trends & Forecast 2026 - 2035
Payal Rabde is a Market Research Analyst specializing in the healthcare, pharmaceuticals, biotechnology, and life science market. She tracks the growing therapy approvals, patient treatment rates, and new collaborations. Her research provides in-depth market intelligence, competitive analysis, and strategic insights to support cell and gene therapy for multiple myeloma growth across the U.S. She also highlighted that CARVYKTI held approximately 80%, while ABECMA held 20% of late-line market share at dual-therapy centres.
Last Updated : 11 September 2026
Category: Life Sciences
Insight Code: 7062
Format: PDF / PPT / Excel